The purpose of the study is to determine whether a shorter, 7‑day course of the antibiotic works as well as the standard 14‑day course in achieving a cure of the infection.

Participants are randomly assigned to receive either the short or the longer treatment. After finishing the medication, they are followed up with visits about two weeks and four weeks later to check whether symptoms have resolved, whether the infection has returned, and whether any side effects have occurred. “Clinical cure” means the patient’s signs and symptoms have returned to normal and no additional antibiotics are needed.

The main purpose of this research is to examine how safe and well-tolerated Vabomere is when used in children aged between 3 months and 12 years who have these urinary tract infections. During the study, participants will need to stay in the hospital initially and receive the medication through an intravenous infusion for at least 3 days. The total treatment period may last between 7 to 14 days.

Throughout the study, doctors will monitor the children’s health by checking their blood and urine samples, vital signs, and any side effects that may occur. They will also look at how the medication moves through the body and how well it works in treating the infection. The medication will be given at regular intervals, with careful attention to the appropriate dose for each child.

The purpose of the study is to understand how Vaborem is absorbed and tolerated in the body of children with these infections. Participants in the study will receive the medication through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will monitor how the medication is processed in the body over a period of time, as well as any side effects that may occur. This will help determine the safety and effectiveness of the medication for treating these infections in children.

Throughout the study, researchers will collect information on how the medication affects the body, including measuring the levels of the drug in the blood at different times. They will also keep track of any changes in the participants’ health, such as side effects or changes in laboratory test results. The study is designed to ensure that the medication is safe and well-tolerated by children with these types of infections.

The purpose of this study is to understand how the body processes these medications, as well as to assess their safety and how well they are tolerated by patients. The study involves participants from birth up to 18 years of age who are hospitalized with cUTI, including acute pyelonephritis. During the study, participants will receive the medication through an intravenous infusion, and their health will be monitored closely to observe how their bodies respond to the treatment.

Participants will be observed for any side effects or changes in their health, and various tests will be conducted to gather information about the medication’s effects. The study aims to provide valuable insights into the use of cefepime and enmetazobactam in treating complicated urinary tract infections in children and adolescents.

The purpose of the study is to determine if the shorter IV-only treatment is as effective as the longer treatment that includes oral antibiotics. The study will monitor the occurrence of kidney scarring, which is a potential complication of the infection, to see if there is any difference between the two treatment methods. Participants will be observed over a period of time, with follow-up checks to assess their recovery and any potential side effects.

Throughout the study, children will be closely monitored for signs of recovery, such as the absence of fever, abdominal pain, and feeding problems. The study will also check for any recurrence of infection and monitor for the presence of antibiotic-resistant bacteria. The trial aims to provide valuable information on the best treatment approach for young children with acute pyelonephritis, ensuring effective care and minimizing potential complications.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients with these infections. Participants in the study will receive one of the treatment combinations or a placebo, and their progress will be monitored over a period of time. The study will involve regular visits to the clinic for check-ups and assessments to see how the infection is responding to the treatment. The goal is to find out which treatment is most effective in curing the infection and preventing it from coming back.

Throughout the study, participants will be closely observed to ensure their safety and to monitor any side effects that may occur. The study aims to provide valuable information that could help improve the treatment of these types of infections in the future. By comparing the different treatment options, researchers hope to identify the best approach for managing cUTI and AP, ultimately leading to better outcomes for patients.

The purpose of the study is to compare the effectiveness of the shorter and longer antibiotic treatments. Participants will be randomly assigned to receive either a 7-day or a 14-day course of antibiotics. The study will monitor the participants’ health and recovery over a period of time to assess the effectiveness of the treatment. This will include checking for the resolution of symptoms such as fever and urinary tract infection signs, as well as ensuring no additional antibiotic treatment is needed up to 30 days after the initial treatment.

Throughout the study, participants will be observed for any potential side effects from the antibiotics and their overall kidney function will be assessed. The study will also track the incidence of any relapse or recurrence of the infection, as well as the presence of antibiotic-resistant bacteria. The goal is to ensure that the shorter treatment is not less effective than the longer one, potentially leading to a change in standard treatment practices for kidney transplant recipients with acute pyelonephritis.